Treatment of COVID-19-associated ARDS with umbilical cord-derived mesenchymal stromal cells in the STROMA-CoV-2 multicenter randomized double-blind trial: long-term safety, respiratory function, and quality of life

CONCLUSIONS: This study suggests a favorable safety profile for the use of intravenous UC-MSCs in the context of the first French wave of SARS-CoV-2-related moderate-to-severe acute respiratory distress syndrome, with no adverse effects observed at 1 year.PMID:38637891 | DOI:10.1186/s13287-024-03729-w

Source: Cell Research - April 18, 2024 Category: Cytology Authors: Alexandre Sitbon Caroline Hauw-Berlemont Miryam Mebarki Nicholas Heming Julien Mayaux Jean-Luc Diehl Alexandre Demoule Djillali Annane Cl émence Marois Sophie Demeret Emmanuel Weiss Guillaume Voiriot Muriel Fartoukh Jean-Michel Constantin Bruno M égarba Source Type: research